Erratum: Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence

Production Office, Frontiers

doi:10.3389/fphar.2022.976792

ERRATUM article

Front. Pharmacol., 18 August 2022

Sec. Pharmacology of Infectious Diseases

Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.976792

Erratum: Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence

This article is an erratum on:

Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence
1. Read original article

Frontiers Production Office*

Frontiers Media SA, Lausanne, Switzerland

An Erratum on
Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence

by Wang C, Yang D, Wang Y and Ni W (2022). Front. Pharmacol. 13:896971. doi: 10.3389/fphar.2022.896971

Due to a production error, the Funding statement was not provided. The correct Funding statement is as follows: This work was supported by the National Natural Science Foundation of China (81903672), Peking University People’s Hospital Research and Development Funds (RS2020-04), and China International Medical Foundation (Z-2018-35-2003). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

The publisher apologizes for this mistake. The original version of this article has been updated. Your article has been copyedited to ensure that we publish the highest quality work possible. Please check it carefully to make sure that it is correct and that the meaning was not lost during the process.

Keywords: cefiderocol, multidrug resistant, carbapenem-resistant, gram-negative bacteria, systematic review

Citation: Frontiers Production Office (2022) Erratum: Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence. Front. Pharmacol. 13:976792. doi: 10.3389/fphar.2022.976792

Received: 23 June 2022; Accepted: 23 June 2022;
Published: 18 August 2022.

Approved by:

Frontiers Production Office, Frontiers Media SA, Switzerland

Copyright © 2022 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Erratum: Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence

94% of researchers rate our articles as excellent or good

94% of researchers rate our articles as excellent or good